Everand Logo

Welcome to Everand!

  • STAT

    Opinion: Don’t let the opioid settlement fritter away funds like the tobacco settlement did

    Money from any forthcoming opioid settlement must be applied to help victims of opioid and other substance use disorders through access to evidence-based care, research, and training.
    by Kathleen T. Brady Sep 12, 2019 3 minutes
    Twenty years after the landmark tobacco settlement, only 2.6% of the funds had been spent on smoking prevention and cessation programs.

    In response to the opioid epidemic in the U.S., cities, counties, states, insurers, and medical groups filed more than 2,000 lawsuits seeking to hold pharmaceutical companies accountable for it. A tentative settlement is now on the horizon: according to news reports on Wednesday, Purdue Pharma will pay up to $12 billion over time and the Sackler family, which owns the company, will give up control of it.

    Opinions abound on how this money should be spent.

    In the midst of this discussion, as a result of opioid overdoses.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks